J.P. Morgan analyst Tessa Romero has maintained their bullish stance on ACAD stock, giving a Buy rating today.
Tessa Romero has given her Buy rating due to a combination of factors that highlight ACADIA Pharmaceuticals’ promising growth trajectory. The company’s revenue guidance for 2025 indicates a significant year-over-year growth, particularly with its key products, Nuplazid and Daybue. ACADIA’s management has set a pragmatic and achievable revenue target exceeding $1 billion in the U.S. market, reflecting confidence in their commercial strategies and the potential for further refinements as the year progresses.
Furthermore, the company’s strategic initiatives, including the expansion of their sales force and direct-to-consumer campaigns, are expected to drive market share and enhance brand awareness. The anticipated increase in sales and marketing expenses is aligned with these growth strategies, supporting both domestic and international commercialization efforts. Additionally, ACADIA’s investment in research and development is set to bolster its clinical programs, potentially leading to new data catalysts in the coming years. These factors collectively contribute to Tessa Romero’s optimistic outlook on ACADIA Pharmaceuticals’ stock.
Romero covers the Healthcare sector, focusing on stocks such as Edgewise Therapeutics, ACADIA Pharmaceuticals, and Cytokinetics. According to TipRanks, Romero has an average return of 13.6% and a 42.03% success rate on recommended stocks.
In another report released today, JMP Securities also reiterated a Buy rating on the stock with a $37.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com